Side Effects of Semaglutide Reported to the U.S. FDA

A comprehensive evaluation of semaglutide's safety profile is warranted due to its expanding clinical use.

• Semaglutide is a glucagon-like peptide-1 receptor agonist used for type 2 diabetes and obesity.
• Adverse event signals associated with semaglutide were characterized using real-world data.
• The study utilized the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
• Findings may provide insights into the safety profile of semaglutide in clinical settings.

Simplified